Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Slides:

Advertisements

Similar presentations

Call 2004: Post-genomic approaches to a human pandemic influenza vaccine Project title: Live attenuated replication-defective influenza vaccine, FLUVACC.

Advertisements

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

0 HHS Influenza Vaccine Projects for NVAC Meeting June 7-8, 2005 By: Dr. Robin Robinson (HHS/OPHEP)

Vaccines and Related Biological Products

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Immunoprophylaxis (prophylactic immunization). Immunoprophylaxis Types of immunization Immunoglobulins and vaccines Strategies in vaccine preparation.

HPV Vaccine Update Eileen Yamada, MD, MPH Immunization Branch California Department of Health Services.

Vaccines Robert Beatty MCB150. Passive vs Active Immunity  Passive immunization transfer of antibodies  Vaccines are active immunizations (mimic natural.

Lab of Immunoregulation

WHO Draft Rapid Response + Containment, May 2006.

National Vaccine Advisory Committee June 7, 2005 Pandemic Influenza Vaccine Research and Development Linda C. Lambert Chief, Respiratory Diseases Branch.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

0 HHS Influenza Vaccine Projects for NVAC Meeting November 29-30, 2005 By: Dr. Robin Robinson Sr. Project Officer ORDC/OPHEP/DHHS.

Vaccines and Related Biological Products Advisory Committee Meeting November 15, 2012 Hepatitis B Vaccine (Recombinant), Adjuvanted (HBV Surface Antigen.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

1 Pandemic Influenza Vaccine Development Pandemic Influenza Vaccine Development sanofi pasteur R&D, France Frederick R. Vogel, Ph.D.

Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

Adaptive Immunity: Understanding cross-reactive responses Lorena E. Brown The University of Melbourne Australia.

Display of the Viral Epitopes on Lactococcus lactis: A Model for Food Grade Vaccine against EV71.

Making Vaccines.

Dr Hannah Kibuuka Makerere University Walter Reed Project Presentation at the Uganda Medical Association-Uganda Veterinary Association joint conference.

Influenza Vaccine Development

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Update on Pandemic Vaccine Development 3 rd WHO WPRO/SEARO NIC Meeting August, 2009, Beijing Masato Tashiro, MD., PhD. Director, WHO Collaborating.

Food and Drug Administration

1 AVIRON COLD-ADAPTED LIVE ATTENUATED INFLUENZA VIRUS VACCINE, TRIVALENT FLUMIST  VRBPAC - July 26, 2001 FDA Clinical Summary ChrisAnna M. Mink, MD.

Effectiveness of Sub-capsular Meningococcal Vaccines An Approach to Evaluate Vaccines for the Prevention of Invasive Group B Meningococcal Disease VRBPAC.

Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.

Immunogenicity of combined vaccines in infants Helena Käyhty, PhD National Public Health Institute Dept of Vaccines Helsinki, Finland.

. A Randomized Clinical Trial of Immunization With Combined Hepatitis A and B Versus Hepatitis B Alone for Hepatitis B Seroprotection in Hemodialysis Patients.

1 Licensure of Pandemic Influenza Vaccines: Demonstration of Effectiveness Vaccines and Related Biological Products Advisory Committee Meeting February.

FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.

VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER Regulatory Approaches & Activities To Support Licensure of Pandemic (H1N1) 2009 Vaccine.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Five: Immunology, Assay Standardization,

Influenza A (H1N1) Vaccine Vaccines and Related Biological Products Advisory Committee Meeting, 23 July 2009 Raburn Mallory, M.D. Proprietary Vaccines.

Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY.

Pandemic Vaccines Current and Future Issues 30 January 2007 Beijing Keiji Fukuda Global Influenza Programme.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute.

Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.

1 Assessment of the Effectiveness of Small Pox Vaccines: Immunogenicity Assay Considerations Freyja Lynn Division of Bacterial, Parasitic and Allergenic.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.

Vaccination Info. Journal of immunology Vaccination of HCWs was associated with reductions in total patient mortality from 17% to 10% (odds ratio [OR],

Design of randomized, double-blind, controlled, multi-center phase IIb trials as part of the EU- funded UNISEC project to assess the safety, immunogenicity.

Marketing Authorisation & Yearly Licence of Influenza Vaccines - „Mock-up” & Pre-Pandemic Influenza Vaccines Zsuzsanna Pauliny MD

1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,

CVD Testing the H1N1 Pandemic Flu Vaccines Mini-Med School Karen Kotloff, MD University of Maryland School of Medicine Center for Vaccine Development September.

Pandemic Influenza Vaccine Manufacture Preparedness Lin Su Sinovac Biotech Co., Ltd.

Viral vaccines .

1 Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine After Priming With an.

SAFETY AND EFFICACY OF MVA85A, A NEW TUBERCULOSIS VACCINE, IN INFANTS PREVIOUSLY VACCINATED WITH BCG: A RANDOMISED, PLACEBO-CONTROLLED PHASE 2B TRIAL Michele.

Utility of Influenza Vaccination for Oncology Patients Daniel A. Pollyea, Janice M.Y. Brown, and Sandra J. Horning Journal of Clinical Oncolgy; Vol 28.

HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK

The more Effective FLU VACCINE PROBLEM

The association between anti-PcrV titers and protective effects against P. aeruginosa in PcrV vaccinated mice Saeko Hamaoka1, Yoshifumi Naito1, Hideya.

HPV Vaccines and Data Needed for Development of Recommendations in the United States Lauri E. Markowitz, MD Centers for Disease Control and Prevention.

Welcome! Thank you for joining the American College of Physicians’ Quality Connect Adult Immunization Learning Series Webinar! We will start in a few.

Novel vaccine adjuvants for infectious diseases aninal

Vaccine development for pandemic influenza

Volume 25, Issue 6, Pages (June 2017)

Case presentation of non-clinical and clinical development of vaccines

Protection from influenza virus challenge.

Human cytomegalovirus vaccine development strategies.

Presentation transcript:

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY

Options for Pandemic Vaccines Inactivated vaccine resembling currently licensed inactivated vaccine Live vaccine resembling currently licensed live vaccine Inactivated vaccines with experimental adjuvants/route of administration Experimental approaches

Inactivated Vaccine Approach Proven technology –Used successfully in 1957 and 1968 –Efficacy data exist for both pandemic and interpandemic years –Large experience with clinical use Largest existing manufacturing capacity Licensing would be relatively straight-forward

Inactivated Vaccine Approach Unlikely to induce mucosal immunity Protection may be strain specific Requires multiple doses Manufacturing capacity limited by availability of eggs and capacity for expansion limited

Evaluation of Unadjuvanted Inactivated H5 Influenza Vaccines Avoid cleavage –Duck Singapore/97 (H5N3) –Recombinant, baculovirus-expressed HA of A/Hong Kong/156/97 (rH5) –Subvirion rgA/Vietnam/1203/04 vaccine (H5N1)

Egg-grown Duck/Singapore Nicholson, et al. Lancet. 2001;357:1937. Study day H5N3 Neutralization GMT

Recombinant rHA H5 Vaccine Insect cell expressing rHA RBCs Purified rHA H5 SDS-PAGE

Neutralization Titers Against A/Hong Kong/156/97 Log2 titer Treanor. Vaccine. 2001;19:1732. Vaccine administered at visit S1 and S3

Response Rates Following One or Two Doses of rHA H5 Vaccine Percent responding* *4-fold or greater increase to a titter of 1:80 with positive WB. Treanor. Vaccine. 2001;19:1732.

Evaluation of rgA/Vietnam/1203/04 (H5N1) Subvirion Vaccine (DMID ) Subjects: Healthy adults ages 18 to 64 Design: Prospective, randomized, double blind Interventions: Two IM doses H5 vaccine separated by 28 days –Placebo, 7.5 mcg, 15 mcg, 45 mcg, 90 mcg –1:2:2:2:2 randomization Endpoints –Safety: solicited and unsolicited AEs –Immunogenicity: neutralizing titer of 1:40

DMID : Preliminary Results Vaccine was well tolerated at all doses Dose related local pain and tenderness Some neutralizing responses seen at all doses Best responses seen at highest doses – only 45 mcg and 90 mcg gave “acceptable” responses Results are very consistent with previous evaluation of rHA H5 vaccine

Strategies to Overcome Poor Responsiveness Booster strategies – include vaccine in annual vaccination, prime population Adjuvant strategies – add adjuvants with dose sparing potential Alternative routes of administration strategies

Strategies to Overcome Poor Responsiveness Booster strategies – include vaccine in annual vaccination, prime population Adjuvant strategies – add adjuvants with dose sparing potential Alternative routes of administration strategies

Age had a Dramatic Effect on the Serum HAI Response to Whole Viron (WV) or Subunit (SU) H9N2 Vaccines Age < 35 yr Age> 35 yr WVSU Stephenson. Lancet. 2003;362:1959.

H1N1 H2N2 H3N2 Effect of H2N2 Exposure on H9N2 Neutralizing Antibody Year of birth Stephenson. Lancet. 2003;362:1959. Pre-vaccine MN antibody titer

Reimmunization with Duck/Singapore Microneutralization GMT Stephenson et al. Vaccine. 2003;21:1687.

Booster Strategies DMID : Boosting of subjects who have previously received rH5 with rgA/VN/1203/04 DMID : Boosting subjects in with a third dose at 6 months Proposed: interaction studies with TIV

Strategies to Overcome Poor Responsiveness Booster strategies – include vaccine in annual vaccination, prime population Adjuvant strategies – add adjuvants with dose sparing potential Alternative routes of administration strategies

Evaluation of Whole Virus H2N2 Vaccine with Alum Study Day GMT HAI Antibody Hehme. et al. Med Microbiol Immunol. 2002;191:203. Virus Res. 2004;103:163.

Evaluation of Whole Virus H9N2 Vaccine with Alum Study Day GMT HAI Antibody Hehme et al. Med Microbiol Immunol. 2002;191:203. Virus Res. 2004;103:163.

Significant Enhancement of the Response to H5N3 Virus with MF59 Nicholson et al. Lancet. 2001;357:1937. No adjuvant MF59 adjuvant Study day H5N3 Neutralization GMT 7.5 ug HA 15 ug HA 30 ug HA

Adjuvant Strategies Alum –H5 formulation – 30 mcg dose met EMEA criteria –H1, H3 vaccines – little enhancement seen in either pandemic or non-pandemic setting –Study – DMID dose ranging H5 on constant alum in healthy adults MF59 –Modest enhancement with TIV –Promising results with H5 vaccines, no obvious dose-response relationship, ? Stochiometry –DMID : significant enhancement of H9 response –Issues: availablility, intellectual property Others: MPL, CPG

Strategies to Overcome Poor Responsiveness Booster strategies – include vaccine in annual vaccination, prime population Adjuvant strategies – add adjuvants with dose sparing potential Alternative routes of administration strategies

Intradermal Vaccination: Post Vaccination GMT and Response Rate (%) GMT post vaccination HI antibody yo> % response 15 mcg IM vs 6 mcg ID

Evaluation of Live Attenuated Vaccines (CAIV) H9 and H5 candidates generated, in clinical trials Highly immunogenic in susceptible populations –Critical need to define correlates of immunity Potential use of low doses –Studies should evaluate full range Induction of mucosal immunity might reduce transmission –Development of challenge models

Evaluation of Live Attenuated Vaccines (CAIV) Potential cross protection –Evaluate responses to range of antigenic variants Not licensed in all populations –Critical need to expand safety database –Define correlates of immunity that could be extended to elderly Concerns regarding transmission and reassortment –Clearly define conditions of deployment, expected shedding patterns, and biologic behavior of reassortants

Experimental Approaches Nasal inactivated vaccines Cross protective peptides/epitopes Virus-like particles Alternative live vaccines Vectored approaches DNA Vaccines

Considerations for Alternate Approaches Validation in clinical studies Extensive safety evaluation Specific markers of efficacy Individualized development strategy Need for early determination of potential advantages against conventional approaches

Critical Issues Is the H5 HA intrinsically less immunogenic? –Mechanism unclear Can cross-protective immune responses be generated? –M2 based immunity –Cross protective epitopes –CTL approaches